Harrow Health Announces $250 Million Notes Offering

An announcement from Harrow Health ( (HROW) ) is now available.

On September 8, 2025, Harrow, Inc. announced the pricing of its $250 million offering of 8.625% senior unsecured notes due 2030. The proceeds from this offering are intended to repay existing debts, including a $107.5 million facility with Oaktree Fund Administration and outstanding senior notes, with any remaining funds to be used for general corporate purposes. This strategic financial move is expected to impact Harrow’s operations by reducing existing debt and potentially funding future business development opportunities.

The most recent analyst rating on (HROW) stock is a Buy with a $42.00 price target. To see the full list of analyst forecasts on Harrow Health stock, see the HROW Stock Forecast page.

Spark’s Take on HROW Stock

According to Spark, TipRanks’ AI Analyst, HROW is a Neutral.

Harrow Health’s overall stock score is driven by strong technical indicators and positive earnings call highlights, including strategic alliances and revenue growth. However, significant financial performance challenges, particularly in profitability and cash flow, weigh heavily on the score. The negative P/E ratio further impacts the valuation, limiting the stock’s attractiveness.

To see Spark’s full report on HROW stock, click here.

More about Harrow Health

Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma, and a range of other ocular surface conditions and retina diseases.

Average Trading Volume: 503,049

Technical Sentiment Signal: Strong Buy

Current Market Cap: $1.37B

See more insights into HROW stock on TipRanks’ Stock Analysis page.